Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral N-acetyl-D-mannosamine - Leadiant Biosciences

Next Previous
Drug Profile

Oral N-acetyl-D-mannosamine - Leadiant Biosciences

Alternative Names: 2-Actamido-2-deoxy-D-mannose; D-ManNAc; DEX-M74; LB-301 - Leadiant Biosciences; LB-701; LB301; ManNAc; N-acetyl-D-mannosamine monohydrate; N-acetyl-mannosamine

Latest Information Update: 22 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Human Genome Research Institute
  • Developer Leadiant Biosciences
  • Class Hexosamines; Small molecules
  • Mechanism of Action Glycosylation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nonaka distal myopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Nonaka distal myopathy
  • Phase I Kidney disorders

Most Recent Events

  • 22 Apr 2022 Phase-III development for Nonaka distal myopathy is ongoing in the US (Leadiant Biosciences pipeline, April 2022)
  • 05 Apr 2022 Leadiant Biosciences and National Human Genome Research Institute initiates the phase II MAGiNE study for Nonaka distal myopathy in USA in February 2020 (PO, Liquid) (NCT04231266)
  • 11 Mar 2022 Leadiant Biosciences plans a phase I trial in Healthy volunteers in Australia, In April 2022 (PO) (IV) (ACTRN12622000394741p)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top